MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,666.45
+0.19%
NASDAQ 100
$30,501.56
+0.31%
DOW JONES
$50,927.00
+0.04%
NASDAQ Composite
$26,871.60
+0.04%
RUSSELL 2000
$2,790.20
+0.41%
CBOE VIX
$16.39
+0.31%
Sector Heatmap
Technology+1.05%
Financials+0.11%
Healthcare-1.32%
Consumer Cycl-0.03%
Consumer Staples-0.33%
Energy+1.95%
Industrials+0.99%
Materials-0.33%
Real Estate-0.56%
Utilities+0.61%
Comm Services-0.93%
CPIX — Cumberland Pharmaceuticals Inc
NasdaqCumberland Pharmaceuticals Inc
$7.51
-0.32(-4.09%)
- O
- 7.90
- H
- 8.14
- L
- 7.26
- V
- 66.63K
⏱️ End-of-day dataAs of Oct 1, 2026
Cumberland Pharmaceuticals Inc Statistics
Total Valuation
| Market Cap | $114.02M |
| Enterprise Value | $114.02M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | 2026-08-03 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | 14.98M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 309,840.88 |
| P/OCF Ratio | 473,118.03 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -34,688.17 |
| EV / Sales | n/a |
| EV / EBITDA | -76,523.50 |
| EV / EBIT | -37,371.36 |
| EV / FCF | 309,837.02 |
Financial Position
| Current Ratio | 0.95 |
| Quick Ratio | n/a |
| Debt / Equity | 0.45 |
| Debt / EBITDA | -6.43 |
| Debt / FCF | 26.05 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | -15.43% |
| Return on Assets (ROA) | -4.63% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-35 |
| Employee Count | 93 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | $4 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | +140.71% |
| 50-Day Moving Average | $7.39 |
| 200-Day Moving Average | $5.26 |
| Relative Strength Index (RSI) | 66.77 |
| Average Volume (20 Days) | 38,525 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | $7.20K |
| Operating Income | -$3.13K |
| Pretax Income | -$3.14K |
| Net Income | -$3.29K |
| EBITDA | -$1.49K |
| EBIT | -$3.05K |
| Loss Per Share | $-0.22 |
Balance Sheet
| Cash & Cash Equivalents | $11.01K |
| Total Debt | $9.59K |
| Net Cash | $1.42K |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | $21.30K |
| Book Value Per Share | $0.00 |
| Working Capital | -$1.70K |
Cash Flow
| Operating Cash Flow | $241 |
| Capital Expenditures | $0 |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | $368 |
| FCF Per Share | $0.00 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
| Dividend Per Share | $1.50 |
| Dividend Yield | 19.97% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | 0.00% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |